Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Giredestrant plus Everolimus in Advanced Breast Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.annonc.2026.05.707
10.1016/j.annonc.2026.05.707 · External reference
10.1200/jco.21.01392
10.1200/jco.21.01392 · External reference
10.1016/j.breast.2024.103756
10.1016/j.breast.2024.103756 · External reference
10.1038/s12276-025-01395-3
10.1038/s12276-025-01395-3 · External reference
10.1016/j.breast.2021.05.008
10.1016/j.breast.2021.05.008 · External reference
10.3892/ijmm.2022.5184
10.3892/ijmm.2022.5184 · External reference
10.1158/0008-5472.can-06-1755
10.1158/0008-5472.can-06-1755 · External reference
10.1158/1078-0432.ccr-20-3624
10.1158/1078-0432.ccr-20-3624 · External reference
10.1007/978-3-031-11836-4_10
10.1007/978-3-031-11836-4_10 · External reference
10.1158/2159-8290.cd-19-1390
10.1158/2159-8290.cd-19-1390 · External reference
10.1016/j.ccell.2018.08.008
10.1016/j.ccell.2018.08.008 · External reference
10.1126/scitranslmed.aac7551
10.1126/scitranslmed.aac7551 · External reference
10.1007/s10549-024-07376-w
10.1007/s10549-024-07376-w · External reference
10.1038/s41523-024-00617-7
10.1038/s41523-024-00617-7 · External reference
10.1200/jco.23.01500
10.1200/jco.23.01500 · External reference
10.1056/nejmoa2410858
10.1056/nejmoa2410858 · External reference
10.1056/nejmoa2505725
10.1056/nejmoa2505725 · External reference
10.1016/j.annonc.2026.05.707
10.1016/j.annonc.2026.05.707 · External reference
10.1021/acs.jmedchem.1c00847
10.1021/acs.jmedchem.1c00847 · External reference
10.1158/1078-0432.ccr-23-1796
10.1158/1078-0432.ccr-23-1796 · External reference
10.1158/1538-7445.am2020-3406
10.1158/1538-7445.am2020-3406 · External reference
A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer.
2020 · External reference
10.1158/1557-3265.sabcs25-ps1-12-11
10.1158/1557-3265.sabcs25-ps1-12-11 · External reference
10.1016/s1470-2045(17)30109-2
10.1016/s1470-2045(17)30109-2 · External reference
10.1016/j.ejca.2008.10.026
10.1016/j.ejca.2008.10.026 · External reference
Unresolved reference
External reference
10.1002/sim.3495
10.1002/sim.3495 · External reference
10.1002/sim.4780131308
10.1002/sim.4780131308 · External reference
10.1200/jco.22.00338
10.1200/jco.22.00338 · External reference
10.1016/s1470-2045(23)00268-1
10.1016/s1470-2045(23)00268-1 · External reference
10.1056/nejmoa2502929
10.1056/nejmoa2502929 · External reference
10.1016/j.annonc.2025.11.018
10.1016/j.annonc.2025.11.018 · External reference
